STOCK TITAN

Nabriva Therapeutics Plc - NBRV STOCK NEWS

Welcome to our dedicated news page for Nabriva Therapeutics Plc (Ticker: NBRV), a resource for investors and traders seeking the latest updates and insights on Nabriva Therapeutics Plc.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Nabriva Therapeutics Plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Nabriva Therapeutics Plc's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.39%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.44%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.44%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.72%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.32%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.34%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.31%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.59%
Tags
conferences earnings
Nabriva Therapeutics Plc

Nasdaq:NBRV

NBRV Rankings

NBRV Stock Data

4.55M
Medicinal and Botanical Manufacturing
Manufacturing
Link
Ireland

About NBRV

nabriva is a clinical-stage biopharmaceutical company engaged in the research and development of novel antibiotics to treat serious infections, with a focus on the pleuromutilin class of antibiotics. our goal is to become a fully integrated biopharmaceutical company focused on the research, development and commercialization of novel anti-infective products. nabriva was incorporated as a spin-off from sandoz gmbh antibiotics research institute (abri) in vienna, austria and commenced operations in february 2006. the new organization included small molecule assets, including pleuromutilin structure activity relationships (sar) knowledge and was focused on synthesis of pleuromutilins for systemic human use. following identification of our lead compound lefamulin and based on the clinical results of lefamulin for acute skin and skin structure infections. we believed that targeted in vitro spectrum of activity for the common pathogens causing community acquired bacterial pneumonia (cabp), wo